- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD20 Antibody rIGEL/773 / MS4A1 Monoclonal Antibody targets CD20, a membrane-associated phosphoprotein encoded by the MS4A1 gene. CD20 belongs to the membrane-spanning 4A (MS4A) protein family and is expressed predominantly during B-cell development, from late precursor stages through mature B lymphocytes. Expression generally declines during differentiation into antibody-secreting plasma cells. This distribution makes CD20 an important marker for investigating B-cell populations, immune regulation, and lymphoid malignancies.
CD20 is an approximately 33-37 kDa protein containing four membrane-spanning regions, intracellular N- and C-terminal domains, and two extracellular loops. Its larger extracellular loop contains epitopes recognized by several therapeutic monoclonal antibodies. Unlike many cell-surface receptors, CD20 does not possess a conventional extracellular ligand-binding domain or intrinsic enzymatic activity. Instead, its biological functions are associated with membrane organization, calcium signaling, and interactions with other proteins involved in B-cell activation.
Although the precise physiological function of CD20 remains incompletely understood, research has linked the protein to the regulation of intracellular calcium homeostasis and B-cell receptor signaling. CD20 can influence calcium responses following antigen receptor engagement, potentially affecting cellular activation, proliferation, and differentiation. Its organization within the plasma membrane and interactions with neighboring signaling components contribute to the complex regulation of B-cell responses.
CD20 is widely investigated in hematologic malignancies, particularly B-cell non-Hodgkin lymphomas and certain B-cell leukemias. Its relatively restricted expression and accessibility at the cell surface have established it as a major target for therapeutic monoclonal antibodies, including rituximab and other CD20-directed agents. Changes in CD20 abundance, membrane distribution, and epitope accessibility can influence therapeutic antibody recognition and treatment responses. CD20 expression may also change following exposure to targeted therapies or during alterations in B-cell differentiation.
Beyond oncology, CD20 has an important role in research involving autoimmune diseases and B-cell depletion strategies. Studying CD20 expression helps clarify the contributions of B lymphocytes to immune activation, antibody-mediated responses, and inflammatory disease mechanisms. CD20 Antibody rIGEL/773 provides a reagent for investigating this established B-cell marker and its relationship to immune cell identity, lymphoid tissue organization, and disease-associated changes in B-cell populations.
Explore additional immune cell markers in our CD Antibodies collection, featuring antibodies targeting proteins involved in lymphocyte development, immune signaling, and cellular identification.
Titering of the CD20 Antibody rIGEL/773 / MS4A1 Monoclonal Antibody may be required for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Human CD20 protein was used as the immunogen for this recombinant CD20 antibody.
Recombinant CD20 antibody with azide can be stored at 2-8oC. The azide-free format should be aliquoted and stored at -20oC or colder.
B-lymphocyte antigen CD20 antibody, B-cell surface antigen B1 antibody, B1 antigen antibody, Membrane-spanning 4-domains subfamily A member 1 antibody, MS4A1 antibody, B-lymphocyte surface antigen B1 antibody, CD20 antigen antibody, CD20 molecule antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.